Welcome to our dedicated page for Ginkgo Bioworks Holdings news (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings stock.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is pioneering the field of synthetic biology by providing an innovative horizontal platform for cell programming. Specializing in flexible, end-to-end services, the company addresses diverse challenges across multiple sectors including food, agriculture, pharmaceuticals, industrial chemicals, and specialty chemicals. Ginkgo Bioworks is organized into two primary segments: Cell Engineering and Biosecurity, with the latter contributing the majority of the company's revenue through data analytics and related services.
One of Ginkgo Bioworks' recent highlights includes the acquisition of AgBiome's platform assets, significantly enhancing its R&D capabilities in agricultural biotechnology. This move has expanded Ginkgo's proprietary metagenomics database, creating a rich resource for AI model development. Furthermore, the company is actively engaged in partnerships to amplify its technological reach, such as its collaboration with Il Granaio delle Idee to enhance sourdough bakery strains and with GreenLab to produce brazzein, a high-intensity sweetener, on a commercial scale.
Ginkgo Bioworks is also a key player in biosecurity, developing advanced infrastructure and technologies to predict, detect, and respond to biological threats. The company's upcoming Biofab1, a fully integrated lab data center expected to open in mid-2025, is part of its strategic plan to streamline operations and achieve adjusted EBITDA breakeven by the end of 2026.
Additionally, Ginkgo's platform is making significant strides in the AI and data generation space, offering services that help clients leverage high-quality data for more effective R&D. Notably, the company recently hosted its 5th annual Ferment conference, where it showcased new products and technological advancements to a global audience.
Despite facing some financial challenges, including a need to regain compliance with NYSE listing standards due to stock price fluctuations, Ginkgo remains committed to its mission. The company continues to innovate and form strategic partnerships, such as its recent agreement with Sojitz Corporation to penetrate the Japanese market, enhancing its role in the global bioeconomy.
For more information, visit ginkgobioworks.com or follow them on social media platforms like X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), and LinkedIn.
FREDsense Technologies partners with Ginkgo Bioworks (NYSE: DNA) to develop biosensors for water quality monitoring. This collaboration aims to create four unique microbial strain biosensors compatible with FREDsense's portable hardware, allowing for real-time detection of harmful molecules in water sources. The partnership addresses the increasing demand for efficient water testing solutions and aims to enhance environmental and public health. CEOs from both companies express excitement about leveraging synthetic biology for critical water safety applications.
On April 12, 2022, Persephone Biosciences and Ginkgo Bioworks (NYSE: DNA) announced a collaboration aimed at developing novel therapeutics utilizing the Bacteroides bacterial genus. The partnership will focus on engineering Bacteroides species as a critical element in microbiome medicines, leveraging Ginkgo's synthetic biology platform. This collaboration is expected to enhance Persephone's capabilities in the microbiome space and could expedite the development of microbial therapies that improve patient outcomes.
Elanco Animal Health and Ginkgo Bioworks have launched BiomEdit, a new company focused on microbiome innovations for animal health. BiomEdit aims to develop probiotics and other solutions addressing urgent needs in livestock health, including antibiotic resistance. With an initial funding of $40 million, BiomEdit will operate independently, utilizing Elanco’s microbiome R&D expertise and intellectual property. This strategic separation allows Elanco to concentrate more effectively on its late-stage pet health pipeline while facilitating the growth of BiomEdit in the animal health sector.
Twist Bioscience Corporation (NASDAQ: TWST) and Ginkgo Bioworks (NYSE: DNA) announced a new four-year supply agreement, enhancing their collaboration in synthetic biology. This agreement marks an increase in Ginkgo's commitments to purchase synthetic DNA from Twist to support its growth across various industries, including vaccine manufacturing and agriculture. The partnership builds on a previous agreement from 2017, highlighting a significant order of approximately one billion base pairs of synthetic DNA.
Microba Life Sciences Limited (ASX: MAP) has commenced trading on the Australian Securities Exchange after raising
Microba Life Sciences (ASX: MAP) and Ginkgo Bioworks (NYSE: DNA) have formed a partnership to identify live bacteria product candidates for autoimmune diseases. Leveraging Ginkgo's high-throughput screening, the collaboration aims to enhance Microba's strain evaluation capabilities. As part of this initiative, Ginkgo is investing $3.5 million in Microba, which is set to launch its Initial Public Offering on April 5, 2022. This partnership highlights the growing interest in microbiome-based therapeutics for chronic diseases.
Ginkgo Bioworks reported strong financial results for 2021, with total revenue reaching $314 million, a remarkable 309% increase from 2020. The company added 31 new Cell Programs, representing a 72% growth year-over-year. Despite a $1.8 billion loss from operations, largely due to stock-based compensation adjustments, Ginkgo maintains a strong cash position with over $1.5 billion. For 2022, Ginkgo anticipates total revenue between $325 million and $340 million and expects to add 60 new Cell Programs.
The joint COVID-19 testing program by Concentric by Ginkgo, the CDC, and XpresCheck identified Omicron sublineages BA.2 and BA.3 ahead of other U.S. reports. This traveler-based genomic surveillance program, conducted at major U.S. airports, enrolled international travelers voluntarily from September 2021 to January 2022. The findings suggest that the program effectively monitors variants and can enhance public health responses. Leaders from the CDC and XpresCheck emphasized its importance in detecting variants and supporting a robust biosecurity infrastructure.
Ginkgo Bioworks (NYSE: DNA) announced a presentation and Q&A session on March 28, 2022, to review business performance for the fourth quarter and full year ended December 31, 2021. The session will begin at 4:30 p.m. ET, with details available on their investor relations site. Additionally, the company will hold its annual shareholder meeting on June 10, 2022, allowing participation through a virtual platform for shareholders of record as of April 14, 2022.
Ginkgo Bioworks (NYSE: DNA) has announced its participation in the Jefferies Virtual Synthetic Biology Week, scheduled for March 22, 2022, at 10:00 a.m. Eastern Time. Management will engage in a fireside chat during this event. Details, including a webcast link and a replay, will be available on the company's investor relations website. Ginkgo operates a platform for cell programming, supporting various biotechnology applications across markets like food, agriculture, and pharmaceuticals, while also contributing to COVID-19 response efforts.
FAQ
What is the current stock price of Ginkgo Bioworks Holdings (DNA)?
What is the market cap of Ginkgo Bioworks Holdings (DNA)?
What does Ginkgo Bioworks do?
What are the main segments of Ginkgo Bioworks?
What recent acquisitions has Ginkgo Bioworks made?
What is Biofab1?
Who are Ginkgo Bioworks' partners?
What is Ginkgo's role in biosecurity?
How is Ginkgo integrating AI in its operations?
What financial challenges is Ginkgo facing?
How can I stay updated with Ginkgo Bioworks' latest news?
When is Ginkgo's next financial update?
